文献速递关节外科

价格与质量错配:加州大型医疗系统内全关节置换术谈判价格是否与医院质量相关

The Price-Quality Mismatch: Are Negotiated Prices for Total Joint Arthroplasty Associated With Hospital Quality in a Large California Health System?
PubMed 文献 · Clin Orthop Relat Res · 2022-12-13

该研究分析加州一个大型区域医疗系统22家医院中4家因质量信息不完整被排除后的数据,评估全关节置换术(TJA)的谈判价格与医院质量是否相关。结果显示TJA总体谈判均价为54,500±23,200美元,不同支付方类型价格差异明显,但各支付方类型的谈判价格与TJA并发症率、再入院率、患者调查星级评分及医院总体绩效评分均无显著相关。作者认为价格与质量存在错配,建议通过匹配的质量与价格报告机制改善价值。

要点

  • TJA总体谈判均价为54,500±23,200美元,Medicare Advantage和Medicaid价格最低,商业保险网络外价格最高。
  • 各支付方类型的谈判价格与TJA并发症率、再入院率均无显著相关。
  • 作者认为价格与质量存在错配,建议通过匹配的质量与价格报告机制改善价值。

核心结论

  • TJA存在大幅价格差异,且该差异不能由医疗质量解释,提示价格与质量之间存在错配。
  • 作者认为需要努力将TJA价格与所提供医疗质量直接挂钩,例如通过匹配的质量与价格报告机制。
  • 作者提出未来研究可探讨向患者公开价格和质量数据(如价值仪表板)是否能推动患者选择更高价值的医疗决策。

研究设计与样本

  • 该研究分析一个大型区域医疗系统内22家医院的公开数据,其中4家因质量信息不完整被排除。
  • 选择单一医疗系统旨在尽量减少医院间声誉或品牌差异以及提供医疗服务成本的地理差异带来的混杂效应。
  • 该医疗系统由服务于城市和农村人群的大大小小医院组成,为超过300万人提供医疗服务。
  • 每家医院的TJA谈判价格分为五种支付方类型:商业保险网络内、商业保险网络外、Medicare Advantage、Medicaid和折扣现金支付。
  • 传统Medicare计划未纳入,因为其价格由法规设定而非谈判确定。

主要发现

  • TJA总体谈判均价为54,500±23,200美元(均值±标准差)。
  • 描述性分析中,最低谈判价格见于Medicare Advantage(20,400±1800美元)和Medicaid(20,300±8600美元)保险计划,最高价格见于商业保险计划覆盖的网络外医疗(78,800±9200美元)。
  • 谈判均价与TJA并发症率无相关性:折扣现金支付r=0.27,p=0.29;商业保险网络外r=0.28,p=0.26;商业保险网络内r=-0.07,p=0.79;Medicare Advantage r=0.11,p=0.65;Medicaid r=0.03,p=0.92。
  • 谈判均价与再入院率无相关性:折扣现金支付r=0.19,p=0.46;商业保险网络外r=0.24,p=0.33;商业保险网络内r=-0.13,p=0.61;Medicare Advantage r=-0.06,p=0.81;Medicaid r=0.09,p=0.74。
  • 谈判均价与患者调查星级评分无相关性:折扣现金支付r=-0.55,p=0.02;商业保险网络外r=-0.53,p=0.02;商业保险网络内r=-0.37,p=0.13;Medicare Advantage r=-0.08,p=0.75;Medicaid r=-0.02,p=0.95。

关键数值与推荐

  • 医院质量指标来自美国联邦医疗保险和医疗补助服务中心(Centers for Medicare and Medicaid Services),包括TJA特异性并发症率和再入院率、全院患者调查星级评分(患者照护体验指标)和总体绩效评分(临床结局、安全性、患者体验、照护过程和效率的综合指标)。
  • 采用Pearson相关系数和Spearman rho评估医院平均谈判价格与质量指标之间的关联。
  • 统计学显著性定义为p<0.0025。

临床怎么用

  • 作者认为,努力将医疗质量与谈判价格更好匹配(如匹配的质量与价格报告机制)可改善TJA的医疗价值。
  • 作者提出,未来研究可探讨向患者公开价格和质量数据(如价值仪表板)是否能推动患者选择更高价值的医疗决策。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Price variations in healthcare can be caused by quality or factors other than quality such as market share, negotiating power with insurers, or hospital ownership model. Efforts to improve care value (defined as the ratio between health outcomes and price) by making healthcare prices readily accessible to patients are driven by the assumption this can help patients more easily identify high-quality, low-price clinicians and health systems, thus reducing price variations. However, if price variations are driven by factors other than quality, then strategies that involve payments for higher-quality care are unlikely to reduce price variation and improve value. It is unknown whether prices for total joint arthroplasty (TJA) are correlated with the quality of care or whether factors other than quality are responsible for price variation. QUESTIONS/PURPOSES: (1) How do prices insurers negotiate for TJA paid to a single, large health system vary across payer types? (2) Are the mean prices insurers negotiate for TJA associated with hospital quality? METHODS: We analyzed publicly available data from 22 hospitals in a single, large regional health system, four of which were excluded owing to incomplete quality information. We chose to use data from this single health system to minimize the confounding effects of between-hospital reputation or branding and geographic differences in the cost of providing care. This health system consists of large and small hospitals serving urban and rural populations, providing care for more than 3 million individuals. For each hospital, negotiated prices for TJA were classified into five payer types: commercial in-network, commercial out-of-network, Medicare Advantage (plans to which private insurers contract to provide Medicare benefits), Medicaid, and discounted cash pay. Traditional Medicare plans were not included because the prices are set statutorily, not negotiated. We obtained hospital quality measures from the Centers for Medicare and Medicaid Services. Centers for Medicare and Medicaid Services quality measures included TJA-specific complication and readmission rates in addition to hospital-wide patient survey star rating (measure of patient care experience) and total performance scores (aggregate measure of clinical outcomes, safety, patient experience, process of care, and efficiency). We evaluated the association between the mean negotiated hospital prices and Centers for Medicare and Medicaid Services quality measures using Pearson correlation coefficients and Spearman rho across all payer types. Statistical significance was defined as p < 0.0025. RESULTS: The mean ± SD overall negotiated price for TJA was USD 54,500 ± 23,200. In the descriptive analysis, the lowest negotiated prices were associated with Medicare Advantage (USD 20,400 ± 1800) and Medicaid (USD 20,300 ± 8600) insurance plans, and the highest prices were associated with out-of-network care covered by commercial insurance plans (USD 78,800 ± 9200). There was no correlation between the mean negotiated price and TJA complication rate (discounted cash price: r = 0.27, p = 0.29; commercial out-of-network: r = 0.28, p = 0.26; commercial in-network: r = -0.07, p = 0.79; Medicare Advantage: r = 0.11, p = 0.65; Medicaid: r = 0.03, p = 0.92), readmission rate (discounted cash price: r = 0.19, p = 0.46; commercial out-of-network: r = 0.24, p = 0.33; commercial in-network: r = -0.13, p = 0.61; Medicare Advantage: r = -0.06, p = 0.81; Medicaid: r = 0.09, p = 0.74), patient survey star rating (discounted cash price: r = -0.55, p = 0.02; commercial out-of-network: r = -0.53, p = 0.02; commercial in-network: r = -0.37, p = 0.13; Medicare Advantage: r = -0.08, p = 0.75; Medicaid: r = -0.02, p = 0.95), or total hospital performance score (discounted cash price: r = -0.35, p = 0.15; commercial out-of-network: r = -0.55, p = 0.02; commercial in-network: r = -0.53, p = 0.02; Medicare Advantage: r = -0.28, p = 0.25; Medicaid: r = 0.11, p = 0.69) for any of the payer types evaluated. CONCLUSION: There is substantial price variation for TJA that is not accounted for by the quality of care, suggesting that a mismatch between price and quality exists. Efforts to improve care value in TJA are needed to directly link prices with the quality of care delivered, such as through matched quality and price reporting mechanisms. Future studies might investigate whether making price and quality data accessible to patients, such as through value dashboards that report easy-to-interpret quality data alongside price information, moves patients toward higher-value care decisions. CLINICAL RELEVANCE: Efforts to better match the quality of care with negotiated prices such as matched quality and price reporting mechanisms, which have been shown to increase the likelihood of choosing higher-value care in TJA, could improve the value of care.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Zhuang T, Shapiro LM, Baker LC, et al. The Price-Quality Mismatch: Are Negotiated Prices for Total Joint Arthroplasty Associated With Hospital Quality in a Large California Health System? Clin Orthop Relat Res. 2022. PMID: 36729581. doi:10.1097/CORR.0000000000002489

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。